Expected spinal cord independence measure, third version, scores for various neurological levels after complete spinal cord lesions

Spinal Cord

Volumn 49, Issue 8, 2011, Pages 893-896

  Aidinoff, E ^a   Front, L ^a   Itzkovich, M ^a,b   Bluvshtein, V ^a,b   Gelernter, I ^b   Hart, J ^a,b   Biering Sorensen F ^c   Weeks, C ^d   Laramee, M T ^e   Craven, C ^f   Hitzig, S L ^f   Glaser, E ^g   Zeilig, G ^b,h   Aito, S ⁱ   Scivoletto, G ^j   Mecci, M ^k   Chadwick, R J ^k   El Masry, W S ^l   Osman, A ^l   Glass, C A ^m   Soni, B M ^m   Gardner, B P ⁿ   Savic, G ⁿ   Bergstrom E M ⁿ   Silva, P ^o   Catz, A ^a,b   more..

^a LOEWENSTEIN REHABILITATION HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d GF STRONG REHABILITATION CENTRE   (Canada)

^e Rehabilitation Institute of Montreal   (Canada)

^f TORONTO REHABILITATION INSTITUTE   (Canada)

^g Neurological Rehab Centre   (Germany)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

^k North of England Spinal Cord Injuries Centre   (United Kingdom)

^l ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^m North West Regional Spinal Injuries Centre ^*  (United Kingdom)

ⁿ STOKE MANDEVILLE HOSPITAL   (United Kingdom)

^o Rovisco Pais Spinal Centre   (Portugal)

more..

Author keywords

complete lesion; injury level; spinal cord independence measure; spinal cord injury; spinal cord lesion

Indexed keywords

ARTICLE; EUROPE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; MIDDLE EAST; NEUROLOGIC EXAMINATION; NORTH AMERICA; PRIORITY JOURNAL; SCORING SYSTEM; SPINAL CORD INDEPENDENCE MEASURE; SPINAL CORD LESION;

ADULT; DISABILITY EVALUATION; EUROPE; HUMANS; INTERNATIONAL COOPERATION; MIDDLE AGED; MIDDLE EAST; NEUROLOGIC EXAMINATION; NORTH AMERICA; OUTCOME ASSESSMENT (HEALTH CARE); RECOVERY OF FUNCTION; REPRODUCIBILITY OF RESULTS; SPINAL CORD INJURIES; YOUNG ADULT;

EID: 80051552178     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2011.32     Document Type: Article

References (55)

1. Whiteneck GG, Charlifue SW, Frankel HL, Fraser MH, Gardner BP, Gerhart KA et al. Mortality, morbidity and psychosocial outcomes of person with spinal cord injury more than 20 years ago. Paraplegia 1992; 30: 617-630. (Pubitemid 23010936)
2. DeVivo MJ, Krause JS, Lammertse DP, DeVivo MJ, Krause JS, Lammerts DP et al. Recent trends in mortality and cause of deaths in persons with spinal cord injury. Arch Phys Med Rehabil 1999; 80: 1411-1419. (Pubitemid 29526638)
3. Bauman WA, Spungen AM. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: A model of premature aging. Metabolism 1994; 43: 749-756. (Pubitemid 24181204)
4. Lipman RL, Raskin P, Love T, Triebwasser J, Lecocq FR, Schnure JJ. Glucose intolerance during decreased physical activity in man. Diabetes 1972; 21: 101-107.
5. Helmrich SP, Ragland DR, Leung RW, Paffenbarger Jr. RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325: 147-152.
6. Yekutiel M, Brooks ME, Ohry A, Yarom J, Carel R. The prevalence of hypertension, ischaemic heart disease and diabetes in traumatic spinal cord injured patients and amputees. Paraplegia 1989; 27: 58-62. (Pubitemid 19070595)
7. Spungen AM, Lesser M, Almenoff PL, Bauman WA. Prevalence of cigarette smoking in a group of male veterans with chronic spinal cord injury. Mil Med 1995; 160: 308-311.
8. Stover SL, Fine PR (eds). Spinal Cord Injury: Facts and Figures. The University of Alabama at Birmingham: Birmingham, AL, 1986, p 13.
9. Brach BB, Moser KM, Cedar L, Minteer M, Convery R. Venous thrombosis in acute spinal cord paralysis. Trauma 1977; 17: 289-292. (Pubitemid 8110850)
10. Perkash A, Perkash V, Perkash I. Experiences with management of thromboembolism in patients with spinal cord injury: Part 1. Incidence, diagnosis and role of risk factors. Paraplegia 1979; 16: 322-331. (Pubitemid 9161558)
11. Lamb GC, Tomski MA, Kaufman J, Maiman DJ. Is chronic spinal cord injury associated with increased risk of venous thromboembolism? J Am Paraplegia Soc 1993; 16: 153-156.
12. Lasslo A (ed). Blood Platelet Function and Medicinal Chemistry. Elsevier Science Publishing Co. Inc.: New York, 1984.
13. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence of enhanced platelet reactivity in vivo. Am J Cardiol 1981; 48: 395-402. (Pubitemid 11014380)
14. DeBoer AC, Turpie AGC, Butt RW, Johnston RV, Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation 1989; 66: 327-333.
15. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205. (Pubitemid 19178653)
16. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-1220.
17. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 74: 2994-2998.
18. Moncada S, Gryglewski R, Bunting S, Vane Jr.. An enzyme isolated from arteries transforms prostaglandin endoperoxidases to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
19. Das UN. Essential fatty acids and their metabolites could function as endogenous. HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008; 7: 37.
20. Sinha AK, Rao AK, Willis J, Colman RW. Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa. Proc Natl Acad Sci USA 1983; 80: 6086-6090. (Pubitemid 14238680)
21. Ignarro LJ. Biosynthesis and metabolism of endothelium derived nitric oxide. Ann Rev Pharmacol Toxicol 1990; 30: 535-560.
22. Marcus AJ, Weksler BB, Jaffe EA. Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid prostacyclin by cultured human endothelial cells. J Biol Chem 1978; 253: 7138-7141. (Pubitemid 9050862)
23. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103: 147-166. (Pubitemid 39209041)
24. Kahn NN. Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gia protein. Life Sci 1998; 63: 2031-2038. (Pubitemid 28522425)
25. Murata T, Ushikubi F. Altered pain perception and inflammatory response in mice lacking Prostacyclin receptors. Nature 1997; 388: 678-682. (Pubitemid 27366439)
26. Cimminiello CG, Arpaia M. Platelet-derived growth factor (PDGF) in patients with different degrees of chronic arterial obstructive disease. Angiology 1994; 45: 289-293.
27. Ross R, Bowen-Pope DF, Raines EW. Platelet-derived growth factor and its role in health and disease. Philos Trans R Soc Lond B Biol 1990; 327: 155-169.
28. Bauman WA, Raza M, Machac J. Tomographic thallium myocardial perfusion imaging after intravenous dipyridamole in asymptomatic subjects with quadriplegia. Arch Phys Med Rehabil 1993; 174: 740-744. (Pubitemid 23203552)
29. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: Characteristics of coronary atherosclerotic plaques. Br Heart J 1883; 50: 127-134.
30. Davies MJ, Thomas AC. The cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985; 53: 363-373. (Pubitemid 15055510)
31. Badimon LH, Cheseboro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992; 86(Suppl): III74-III85.
32. Coughlin SR, Vu T, Hing D, Wheaton V. Characterization of a functional thrombin receptor. J Clin Invest 1992; 89: 351-355.
33. Shultz PJ, Knauss TC, Mené P, Abboud HE. Mitogenic signals for thrombin in mesangial cells: Regulation of phospholipase C and PDGF genes. Am J Physiol 1989; 257(Part 2): F366-F374.
34. Kahn NN, Sinha AK. Stimulation of prostaglandin E1 binding to human platelet membrane by insulin and the activation of adenylate cyclase. J Biol Chem 1990; 265: 4976-4980.
35. Karamouzis M, Karamouzis I, Vamvakoudis E, Ampatzidis G, Christoulas K, Angelopoulou N et al. The response of muscle interstitial prostaglandin E(2)(PGE(2)), prostacyclin (2)(PGI2) and Thromboxane A(2) (TXA(2) levels during incremental dynamic exercise in humans determined by in vivo microdialysis. Prostaglandin Leukot Essent Fatty Acids 2001; 64: 259-263. (Pubitemid 32620000)
36. Brüne B, Ullrich V. Cyclic nucleotides and intracellularcalcium homeostasis in human platelets. Eur J Biochem 1992; 207: 607-613.
37. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 1994; 267(Part 1): C236-C244.
38. Kahn NN, Bauman WA, Sinha AK. Insulin-induced release of platelet plasminogen activator from human blood platelets. Am J Physiol 1995; 37: H117-H124.
39. Kahn NN, Bauman WA, Sinha AK. Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandininduced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. Proc Natl Acad Sci USA 1996; 93: 245-249. (Pubitemid 26038136)
40. Kahn NN. Platelet-stimulated thrombin generation and platelet derived growth factor are normalized by insulin and Ca2+ channel blockers. Am J Physiol Endrocrinol 1999; 276: E856-E862. (Pubitemid 29249604)
41. Kahn NN, Sinha AK. Inhibition of prostaglandin E1 induced activation of adenylate cyclase in human blood platelet membrane. Biochim Biophys Acta 1988; 972: 45-53.
42. Kahn NN, Bauman WA, Sinha AK. Demonstration of a novel circulating anti-prostacyclin receptor antibody. Proc Natl Acad Sci USA 1997; 94: 8779-8782. (Pubitemid 27335116)
43. Kahn NN, Bauman WA, Sinha AK. Appearance of a novel prostacyclin receptor antibody and duration of spinal cord injury. J Spinal Cord Med 2005; 28: 97-102. (Pubitemid 43100816)
44. Gibson AE, Buchholz AC, Martin Ginis KA. SHAPE-SCI research group. C-reactive protein in adults with chronic spinal cord injury: Increased chronic inflammation in tetraplegia vs paraplegia. Spinal Cord 2008; 46: 616-621.
45. Demirel S, Demirel G, Tükek T, Erk O, Yilmaz H. Risk factors for coronary heart disease in patients with spinal cord injury in Turkey. Spinal Cord 2001; 39: 134-138. (Pubitemid 32336987)
46. LaPorte RE, Brenes G, Dearwater S, Murphy MA, Cauley JA, Dietrick R et al. HDL cholesterol across a spectrum of physical activity from quadriplegia to marathon running. Lancet 1983; 1: 1212-1213.
47. Kahn NN, Bauman WA, Sinha AK. Circulating heavy chain IgG a pathologic mediator of coronary artery disease recognizes platelet surface receptors of both prostacyclin and insulin. Platelets 2003; 14: 203-210. (Pubitemid 36791839)
48. Kahn NN, Muellar HS, Sinha AK. Restoration by insulin of impaired prostaglandin E1/I2 receptor activity of platelets in acute ischemic heart disease. Circ Res 1991; 68: 245-254.
49. Acharya K, Battacharya S, Acharya R, Kahn NN, Sinha AK. Purification and properties of insulin activated nitric oxide synthase. Arch Biophys Biochem 2002; 109: 441-449.
50. Sinha AK, Bhattacharya S, Acharya K, Mazumder S, Bauman WA, Kahn NN. Prevention of thrombosis in vivo nitric oxide. Ind J Physiol Allied Sci 1998; 52: 148-161.
51. Trovati M, Anfossi G, Massucco P, Mattiello L, Costamagna C, Piretto V et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate. Diabetes 1997; 46: 742-749. (Pubitemid 27188249)
52. Wang CX, Nuttin B, Heremans H, Dom R, Gybels J. Production of tumor necrosis factor in spinal cord following traumatic injury in rats. J Neuroimmunol 1996; 69: 151-156. (Pubitemid 26305640)
53. Dong G, Ye R, Shi W, Liu S, Wang T, Yang X et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 2003; 116: 543-548. (Pubitemid 36675854)
54. Davies AL, Hayes KC, Dekaban GA. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1384-1393. (Pubitemid 47625318)
55. Hayes KC, Hull TC, Delaney GA, Potter PJ, Sequeira KA, Campbell K et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 2002; 19: 753-761. (Pubitemid 34761337)